Showing 9,101 - 9,120 results of 18,134 for search 'significantly ((((((nn decrease) OR (linear decrease))) OR (a decrease))) OR (larger decrease))', query time: 0.49s Refine Results
  1. 9101

    Image 2_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”
  2. 9102

    Image 5_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”
  3. 9103

    Data Sheet 1_Burden of falls in China, 1992–2021 and projections to 2030: a systematic analysis for the global burden of disease study 2021.xlsx by Liang Sui (20912441)

    Published 2025
    “…Joinpoint regression analysis revealed fluctuating trends in prevalence and incidence with periods of increase and decline, and a general decrease in mortality except during brief intervals. …”
  4. 9104

    Data_Sheet_1_Neuroprotection by upregulation of the major histocompatibility complex class I (MHC I) in SOD1G93A mice.docx by Ana Laura M. R. Tomiyama (16902930)

    Published 2024
    “…Disease progression upregulated gene transcripts for pro- and anti-inflammatory cytokines, and IFN β treatment significantly decreased mRNA expression for IL4. Overall, the present results demonstrate that a low dosage of IFN β shows therapeutic potential by increasing MHC-I expression, resulting in neuroprotection and immunomodulation.…”
  5. 9105
  6. 9106

    Supplementary Material for: Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration‑resistant prostate cancer: a single-center, open-label... by Yu J. (3610580)

    Published 2024
    “…The median time to PSA50 in the Darolutamide group was 1.5 months (95%CI 0.2619- 0.9545), significantly lower than that in the placebo group (3.0 months [95%CI 1.048- 3.818], p= 0.0259); The median time to PSA90 in the experimental group was 4 months (95%CI 0.3094- 1.437), 2 months shorter than that in the placebo group (6.0 months [95%CI 0.6961- 3.232]).With the median follow-up of 6 months, , the median decrease in serum PSA was -81.8% (range -60.4 to -99.9%) in the Darolutamide group and -69.4% (range -50.3 to -89.6%) in the placebo group. …”
  7. 9107

    Supplementary Material for: Albumin and platelet loss during the application of CytoSorb® in critically ill patients: a post-hoc analysis of the Cyto-SOLVE trial by Brozat C.I. (20130933)

    Published 2024
    “…However, a significant albumin decrease was observed in those 17 patients with less than 20g albumin substitution during CS therapy (p=0.007, mean 0.17g/dL, 95% CI 0.05 – 0.29). …”
  8. 9108

    Supplementary tables: Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study by Malgorzata Ciepielewska (22143499)

    Published 2025
    “…The intermediate versus early group had a significantly greater proportion of patients with unmet treatment needs (p < 0.001), e.g., slowing disease progression, providing neuroprotection. …”
  9. 9109

    Data Sheet 1_Glucocorticoids and immunoglobulin alone or in combination in the treatment of multisystemic inflammatory syndrome in children: a systematic review and network meta-an... by Junjie Lin (8379594)

    Published 2025
    “…When compared to combination therapy, GCs monotherapy was associated with a reduction in ICU length of stay [SMD −0.25, 95% CI (−0.85, 0.36)], duration of fever (SMD [−0.42, 95% CI (−0.73, −0.11)], and duration of inotropic support [SMD −0.13, 95% CI (−0.46, 0.20)], as well as a decrease in the incidence of left ventricular (LV) dysfunction [OR 0.96, 95% CI (0.55, 1.68)]. …”
  10. 9110

    Supplementary data: Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study by Malgorzata Ciepielewska (22143499)

    Published 2025
    “…The intermediate versus early group had a significantly greater proportion of patients with unmet treatment needs (p < 0.001), e.g., slowing disease progression, providing neuroprotection. …”
  11. 9111

    Table 1_Has carbon finance been able to promote clean energy development? — a low-carbon technology innovation perspective.xlsx by Rui Cui (622759)

    Published 2025
    “…It is found that carbon finance significantly promotes clean energy development, but this contribution decreases with the intervention of low-carbon technology innovation. …”
  12. 9112

    Data Sheet 1_Effectiveness of community-based management models in chronic obstructive pulmonary disease: a systematic review and meta-analysis.docx by Miao Zhan (2625718)

    Published 2025
    “…Notably, neither approach demonstrated a statistically significant advantage in improving quality of life among COPD populations, as assessed by the St. …”
  13. 9113
  14. 9114

    Data Sheet 1_Systemic lipid and glucose modulation differentially affects cognitive function and neuroinflammation in a mouse model of Alzheimer’s disease.xlsx by Demos Kynigopoulos (12420457)

    Published 2025
    “…Introduction<p>Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by synaptic dysfunction and cognitive decline. …”
  15. 9115

    Table 1_Carnosine as a protective metabolic mediator in inflammatory lung injury by inhibiting macrophage infiltration and M1-like polarization.docx by Lianjie Ruan (22660265)

    Published 2025
    “…Multiplex immunofluorescence further demonstrated a significant reduction of macrophage accumulation in the peribronchial regions of the lung following carnosine administration. …”
  16. 9116

    Table 2_Carnosine as a protective metabolic mediator in inflammatory lung injury by inhibiting macrophage infiltration and M1-like polarization.xlsx by Lianjie Ruan (22660265)

    Published 2025
    “…Multiplex immunofluorescence further demonstrated a significant reduction of macrophage accumulation in the peribronchial regions of the lung following carnosine administration. …”
  17. 9117
  18. 9118

    Data Sheet 1_α-methyltryptophan-mediated protection against diabetic nephropathy in db/db mice as studied with a metabolomics approach.docx by Aimin Cai (6190532)

    Published 2025
    “…</p>Results<p>The results of the study demonstrated that α-MT significantly reduced the urinary excretion of albumin and creatinine, improved kidney function, and decreased renal fibrosis in db/db mice. …”
  19. 9119

    Supplementary file 1_Systemic lipid and glucose modulation differentially affects cognitive function and neuroinflammation in a mouse model of Alzheimer’s disease.docx by Demos Kynigopoulos (12420457)

    Published 2025
    “…Introduction<p>Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by synaptic dysfunction and cognitive decline. …”
  20. 9120

    Data Sheet 1_Impact of the SARS-COV-2 pandemic on access to health services in Angola: a focus on diagnosis and treatment services for tuberculosis.docx by Susanna Caminada (16789893)

    Published 2025
    “…</p>Results<p>There was a significant decline in access to TB services during the pandemic, with a substantial decrease in reported cases (−15.5% in 2020; −18.3% in 2021) and treatment rate (from 86% in 2019 to 68% in 2020), an increase in multidrug-resistant-TB (from 0.2% in 2018 to 2.1% in 2022) and TB/HIV co-infections (from 6% in 2018 to 8.8% in 2021). …”